Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 5 versus GOZELLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 5 versus GOZELLIX.
ADDERALL XR 5 vs GOZELLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 5 contains a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
GOZELLIX (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It competitively binds to GnRH receptors in the anterior pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing ovarian estrogen and testicular testosterone production.
20 mg orally once daily in the morning
250 mg subcutaneously once monthly.
None Documented
None Documented
d-Amphetamine: 10-13 hours (adults), 11-14 hours (children); l-Amphetamine: 13-15 hours (adults). The prolonged terminal half-life of the extended-release formulation supports once-daily dosing.
Terminal elimination half-life: 14–16 hours in healthy adults; prolonged in renal impairment (up to 30 hours in ESRD).
Renal (approximately 90% as unchanged drug and metabolites, with 30-40% as unchanged amphetamine), fecal (minimal, <5%)
Primarily renal (approx. 80%) as unchanged drug; biliary/fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant